Medicare Walks Back Proposed Payment Policy For 505(b)(2) Physician Administered Drugs

CMS acknowledges stakeholders may need more details about the plan before it is finalized and a delay will give the agency more time to ‘consider the issue.’

Infusion of a hospital
Effort Targeted At Part B Drug Costs

More from Medicare

More from Government Payers